OGRD Alliance · Powered by STIP™
Building the operating architecture for patient-specific biotechnology.
PLPC™ Platform is a proprietary biotechnology infrastructure that connects structural immunobiology, patient-specific execution, localized medical devices, precision healthspan systems and an AI-ready immunobiological intelligence graph.
PLPC™ Platform builds the architectures. ONCOVIX™ translates them into patient-specific execution. STIP™ turns every execution into connected intelligence.
One IP core. Multiple execution engines. Compounding platform value.
PLPC™ Platform is designed as a multivertical biotechnology infrastructure. The products create market access. The executions generate evidence. The graph compounds platform value.
Clinical Translation
ONCOVIX™ · PLPC-DB™
Patient-specific execution, longitudinal evidence and biomedical upside.
Localized Devices
APHELAR™
Device-led market access and localized interface development.
Precision Healthspan
ABIMPROSYC™
Commercial entry through defense, recovery, vitality and performance.
Intelligence & Moat
STIP™ · FSI™
Connected evidence, comparability, diligence and BioAI optionality.
Beyond single-target biotechnology
PLPC™ Platform proposes a different category: Structural Immunobiological Intelligence. It studies how receptors, membranes, proteins and longitudinal evidence are organized as a system.
Conventional Biotechnology Asks...
- What molecule is present?
- What receptor is expressed?
- What biomarker changed?
- What product was administered?
PLPC™ Platform Asks...
- How is the molecular system organized?
- Is the receptor structurally and functionally integrated?
- What trajectory and context produced the change?
- Which version, lot, protocol and follow-up were involved?
Eight Foundational Mechanisms (M1–M8)
A framework for scientific interrogation, architecture design and evidence organization.
ONCOVIX™: The Patient-Specific Execution Pathway
ONCOVIX™ is where PLPC™ Platform moves from architecture to individual execution. It is the operational layer through which clinical complexity, biological context, conventional treatment, functional status and biomarkers are evaluated around one person.
STIP™: The Immunobiological Intelligence Graph
STIP™ is the intelligence infrastructure that makes PLPC™ operational, auditable and scalable. It connects product identity, formulation, lot history, protocol, baseline, biomarkers, functional execution, reports, evidence packages and claims control.
The graph is the asset: connected evidence compounds in value over time.
Enter the STIP™ Graph
Differentiated Routes to Market
Common architecture does not mean interchangeable products. Each engine opens specialized, defensible commercial pathways.
APHELAR™ · Localized Medical Devices
Translates PLPC™ Platform principles into localized medical-device and interface configurations (IO, TOL, REG). Each product preserves its own intended use, material specifications, quality controls and territorial documentation.
Explore APHELAR™ Pathway →ABIMPROSYC™ · Precision Healthspan
The functional nutraceutical family of PLPC™ Platform. Formulated around specific functional territories: T-Defense™, Regenera™, Vitalis™ and SPORT™, backed by Whole-Matrix evaluation and STIP™ traceability.
Discover ABIMPROSYC™ →High-technology positioning requires high-discipline governance.
PLPC™ Platform separates platform from product, program from candidate, mechanism from outcome, evidence from inference, and current capability from future optionality.
Partner in the future of structural immunobiological intelligence.
Multiple entry points into one platform architecture: territorial licensing, vertical partnerships, joint development and Data Room access.